IL17A
IL17A is the signature cytokine of the Th17 lineage, acting as a master regulator of barrier inflammation. It is the primary driver of tissue damage in psoriasis and ankylosing spondylitis but is essential for defense against fungal infections.
Key Takeaways
- •IL17A is the primary "weapon" used by Th17 cells to trigger tissue-level inflammation.
- •It is the definitive driver of skin plaques in psoriasis and joint erosion in psoriatic arthritis.
- •IL17A is essential for clearing Candida (yeast) and other fungal infections from the skin and gut.
- •Targeting IL17A with biologics (e.g., Secukinumab) provides rapid and near-complete skin clearance in most psoriasis patients.
Basic Information
- Gene Symbol
- IL17A
- Full Name
- Interleukin 17A
- Also Known As
- IL-17IL-17ACTLA8
- Location
- 6p12.2
- Protein Type
- Cytokine / Inflammatory Mediator
- Protein Family
- Interleukin-17 family
Related Isoforms
Key SNPs
The most studied IL17A variant; the A allele is associated with increased cytokine production and higher risk of psoriasis and ulcerative colitis.
Associated with differential mRNA stability; studied in relation to the severity of inflammatory joint disease.
Common marker used in GWAS to identify the IL17A/F cytokine cluster on chromosome 6.
Overview
Interleukin 17A (IL17A) is a pro-inflammatory cytokine that plays a dual role as both a vital defender of the body’s barriers and a destructive agent of autoimmunity. It is primarily produced by Th17 cells, a specialized subset of T-helper cells, as well as by innate cells like γδ T-cells and ILC3s. Its main physiological function is to recruit neutrophils to sites of infection and to strengthen the defense of the skin and mucous membranes.
In autoimmune conditions, IL17A production becomes chronic and uncontrolled. It acts directly on keratinocytes in the skin, fibroblasts in the joints, and epithelial cells in the gut, forcing them to churn out additional inflammatory chemicals and matrix-degrading enzymes. This creates a self-sustaining loop of tissue destruction that is the hallmark of diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Conceptual Model
A simplified mental model for the pathway:
IL17A is the body's attempt to rapidly reinforce the perimeter against invasion.
Core Health Impacts
- • Neutrophil Recruitment: Drives the production of chemokines like CXCL8 to bring neutrophils to tissues
- • Keratinocyte Growth: Forces skin cells to multiply rapidly, leading to the formation of scales and plaques
- • Fungal Defense: Essential for the clearance of Candida and other opportunistic fungal pathogens
- • Bone Remodeling: Promotes both bone resorption (erosion) and pathological new bone formation
- • Vascular Stiffness: Systemic IL17A elevation contributes to endothelial dysfunction and arterial aging
Protein Domains
Homodimer Interface
IL17A functions as a disulfide-linked homodimer, a structure required for binding the IL-17RA/RC complex.
Cysteine Knot
A conserved structural motif that provides the rigid framework necessary for extracellular signaling.
Upstream Regulators
IL-23 Activator
The master survival factor for Th17 cells; its signal is a prerequisite for sustained IL17A production.
IL-6 / TGF-β Activator
The cytokine pair that initially instructs a naive T-cell to become a Th17 cell.
Th17 Cells Activator
The primary adaptive immune source of IL17A in chronic inflammatory disease.
ILC3s Activator
Innate lymphoid cells that provide rapid, "front-line" IL17A production at mucosal surfaces.
γδ T-cells Activator
A specialized T-cell subset that produces IL17A independently of traditional MHC recognition.
Downstream Targets
IL-17 Receptor (IL-17RA/RC) Activates
The heterodimeric receptor complex that initiates the intracellular signaling cascade.
ACT1 (TRAF3IP2) Activates
The essential adaptor protein that links the IL-17 receptor to the NF-κB pathway.
NF-κB Activates
Master transcription factor for the secondary wave of inflammatory cytokine production.
Neutrophil Chemokines (IL-8) Activates
Upregulated by IL17A to recruit "clean-up" immune cells to the site of inflammation.
Keratinocyte Proliferation Activates
The defining effect in the skin; IL17A causes the rapid overgrowth seen in psoriasis.
Osteoclastogenesis Activates
Stimulates the maturation of bone-eating cells, leading to joint destruction in arthritis.
Role in Aging
IL17A is a central driver of the "Type 2 Inflammaging" process. As we age, the cumulative burden of environmental insults and cellular senescence favors the Th17 pathway, leading to a systemic rise in IL17A that accelerates the biological aging of the skin, heart, and joints.
Skin Aging (Barrier)
Chronic IL17A signaling disrupts the normal maturation of skin cells, leading to a thinner, more fragile, and less resilient epidermal barrier.
Vascular Remodeling
Persistent IL17A promotes arterial stiffening and the formation of atherosclerotic plaques by recruiting inflammatory cells into the vessel wall.
Joint Decay
By upregulating bone-resorbing osteoclasts, IL17A accelerates the age-related erosion of cartilage and bone in the joints.
SASP Amplification
IL17A works in synergy with senescent cells to amplify their inflammatory output, turning local senescence into a systemic aging signal.
Neuroinflammation
IL17A can cross the blood-brain barrier in aging, where it activates microglia and contributes to cognitive decline and neurodegeneration.
Intestinal Permeability
Age-related dysbiosis can trigger excess IL17A in the gut, which may paradoxically weaken the epithelial barrier if not properly regulated.
Disorders & Diseases
Psoriasis
The definitive IL17A disease. Chronic signaling forces skin cells into a hyper-active growth state, creating thick, scaly, and painful plaques.
Psoriatic Arthritis
Occurs when the IL17A axis attacks the joints and entheses, leading to pain, swelling, and irreversible structural damage.
Ankylosing Spondylitis
An inflammatory arthritis of the spine where IL17A drives the inflammation that leads to pathological new bone formation and spinal fusion.
Axial Spondyloarthritis
Part of the same spectrum as AS, where IL17A-driven inflammation affects the sacroiliac joints and spine.
Chronic Mucocutaneous Candidiasis
A condition caused by genetic *deficiency* in IL17A signaling, resulting in persistent and severe yeast infections of the skin and nails.
The IBD Paradox
While IL17A is bad for the skin and joints, blocking it in the gut can actually *worsen* Crohn’s disease, highlighting its protective role in intestinal barrier repair.
Interventions
Supplements
Polyphenol studied for its ability to modulate the Th17 response and potentially dampen IL17A signaling efficiency.
Essential regulator of the Th17/Treg balance; low levels are strongly associated with higher IL17A activity and worse disease outcomes.
Reported to influence the SIRT1 pathway, which can inhibit the master Th17 transcription factor RORγt.
Help shift the inflammatory tone of the body away from the pro-autoimmune Th17 state.
Lifestyle
UV radiation (specifically narrow-band UVB) is a therapeutic used to suppress IL17A-producing cells directly in the skin.
Supports the production of SCFAs in the gut, which are natural regulators that keep Th17 cells in check.
Chronic stress can exacerbate Th17-mediated flares; mindfulness and sleep support the body's natural anti-inflammatory brakes.
Smoking is a potent activator of the Th17 pathway and significantly increases the severity of IL17A-driven diseases.
Medicines
Monoclonal antibody that binds and neutralizes the IL17A cytokine directly; highly effective for psoriasis and AS.
Another high-affinity IL17A inhibitor used for rapid skin clearance and joint protection.
Blocks the IL-17RA subunit of the receptor, shutting down the signaling of multiple IL-17 family members (A, F, and A/F).
A dual inhibitor that targets both IL-17A and IL-17F, providing even deeper levels of skin clearance in some patients.
Lab Tests & Biomarkers
Inflammatory Markers
Systemic marker used to track the activity of IL17A-driven inflammation in the joints and spine.
Often elevated in tandem with CRP during active flares of Th17-mediated disease.
Genetic Screening
Testing for the promoter variant to assess the genetic predisposition to high cytokine output and autoimmunity.
Identifies mutations in the signaling adaptor that can cause either hyper-inflammation or immune deficiency.
Activity Assays
Can be measured via ELISA, though levels are often low due to rapid tissue uptake and local action.
Research marker using flow cytometry to identify the percentage of IL17A-producing cells in the blood.
Hormonal Interactions
Estrogen Modulator
Generally promotes the Th17 pathway; explains the increased severity of many IL17A diseases in women.
Cortisol Inhibitor
Glucocorticoids are the body's primary brake on IL17A transcription and Th17 cell expansion.
Progesterone Modulator
Can influence the allergic and autoimmune flares that occur in rhythm with the menstrual cycle.
Leptin Activator
High levels in obesity act as a pro-inflammatory stimulus that specifically favors the Th17/IL-17 axis.
Deep Dive
Network Diagrams
The IL-17 Barrier Defense & Injury Loop
The Effector of the Barrier: IL17A and Tissue Defense
To understand IL17A, one must view it as the “rapid reinforcement” signal for the body’s barriers. While other cytokines act on distant immune cells, IL17A acts directly on the “brick and mortar” of the body: the epithelial cells of the skin, lungs, and gut.
Keratinocyte Activation: In the skin, IL17A tells keratinocytes to multiply faster and to produce their own antimicrobial chemicals. This is a survival mechanism designed to quickly repair a wound or seal off a fungal infection.
Neutrophil Recruitment: IL17A is the body’s primary way of “calling the infantry.” It induces the production of chemokines (like IL-8) that pull neutrophils out of the blood and into the tissue. This ensures a massive cellular defense is present wherever the IL17A signal is active.
The Psoriasis Loop: Runaway Reinforcement
In psoriasis, this defense mechanism becomes a runaway train. Instead of turning on briefly to heal a wound, the IL17A signal stays “on” permanently.
The Scaly Plaque: The skin cells multiply so fast that they cannot mature properly. They pile up on the surface, creating the characteristic thick, red, scaly plaques of psoriasis.
The Feed-forward Fire: This excessive growth further stresses the tissue, which recruits even more Th17 cells, which release even more IL17A. This “feed-forward loop” is why psoriasis is so persistent and hard to treat with simple creams. Modern biologics break this loop by “vacuuming up” the IL17A cytokine, allowing the skin cells to return to their normal, slow growth rate within weeks.
The ACT1 Adaptor: A Unique Signaling Hub
Unlike the majority of interleukins that use the JAK/STAT pathway, IL17A uses a completely different molecular machinery.
The SEFIR Domain: The IL-17 receptor has a unique structural tail called a SEFIR domain. When IL17A binds to the receptor, it recruits a vital adaptor protein called ACT1 (also known as TRAF3IP2).
The Inflammation Switch: ACT1 acts as the bridge that connects the receptor to the NF-κB and MAPK pathways. This unique signaling hub is why IL-17 inhibitors are so specific; they shut down this “barrier-specific” inflammatory fire without broadly suppressing the rest of the immune system’s signaling pathways. Individuals with genetic mutations in ACT1 often suffer from the same yeast infections as those who lack IL17A itself, proving that this adaptor is the essential “engine” of the IL-17 response.
Practical Note: The Yeast Risk
Candida monitoring is required. Because IL17A is the primary defender against yeast, patients on IL-17 inhibitors (like Cosentyx or Taltz) have an increased risk of oral or genital thrush. This is a predictable "on-target" effect of the medication and is usually easily managed.
Gut caution. If a patient has a history of Crohn’s disease or ulcerative colitis, IL-17 inhibitors should generally be avoided, as blocking this pathway in the gut can lead to severe flares of inflammatory bowel disease.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The definitive review of the biology, signaling, and clinical significance of the IL-17 cytokine family.
The pivotal ERASURE and FIXTURE trials that established IL-17A inhibition as a gold-standard therapy for psoriasis.
Proved the role of IL17A in promoting the vascular stiffening and inflammation associated with biological aging.
Elucidated the unique molecular mechanism by which the IL-17 receptor uses the ACT1 adaptor to trigger inflammation.
Detailed the complex, organ-specific role of IL17A in maintaining intestinal barrier health vs driving systemic disease.